Compare Ishares Msci Brazil ETF (EWZ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Smith & Nephew plc — how do they compare? Ishares Msci Brazil ETF trades at $33.78, while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while Ishares Msci Brazil ETF pays none, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| EWZ | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $38.70 |
52-Week Low | $27.36 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $33.86, down 3.78% in the last session. Technical indicators are bearish overall, with moving averages signaling sell pressure, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC taking a $3.06 million position as of August 5, 2026, and Allspring Global Investments increasing its stake significantly in July 2026. The fund offers exposure to Brazilian equities, with a dividend announced for June 2026.
The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist for value-seeking investors given Brazil's market potential, but risks include U.S. tariff impacts (Reuters, July 16, 2026) and competition from lower-cost ETFs like FLBR, which offers a higher dividend yield (Seeking Alpha, July 16, 2026).
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
